Omentin-1 May Be One Treatment Factor for Intravenous Thrombolysis of Acute Cerebral Infarction Through the...

Area of Science:

• Neuroscience
• Biochemistry
• Pharmacology

Background:

• Acute cerebral infarction (ACI) presents significant morbidity and mortality.
• Antiplatelet therapy is a standard treatment for ACI.
• The role of omentin-1 in ACI thrombolysis requires investigation.

Purpose of the Study:

• To investigate the effects of omentin-1 on intravenous thrombolysis for acute cerebral infarction.
• To explore the correlation between omentin-1 levels and clinical outcomes in ACI patients.

Main Methods:

• Established a mouse model of ACI via middle cerebral artery occlusion (MCAO).
• Utilized murine BV2 microglial cells treated with lipopolysaccharide (LPS) and adenosine triphosphate (ATP).
• Assessed omentin-1 mRNA and serum levels in ACI patients and correlated them with clinical scores and inflammatory markers.

Main Results:

• Omentin-1 mRNA expression was down-regulated in ACI patients undergoing thrombolysis.
• Serum omentin-1 levels negatively correlated with NIHSS scores and IL-1β/MMP-2, but positively with Barthel index/hs-CRP.
• In vitro, omentin-1 reduced inflammation, oxidative stress, and enhanced AMPK activity by modulating NLRP3 ubiquitination.

Conclusions:

• Omentin-1 mitigates neuroinflammation and oxidative stress in ACI via AMPK-mediated NLRP3 inhibition.
• Omentin-1 demonstrates potential as a therapeutic agent for ACI intravenous thrombolysis.